Aurora Daljit Singh 的 Form 4 申報
Neumora Therapeutics, Inc.（NMRA），2026/8/21 申報
- 申報編號
- 0001610717-26-000385
- 申報時間
- 2026/8/21 19:10 ET
- 交易日
- 2026/8/20-8/21
- 申報延遲
- 1 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 9 筆非衍生性交易、6 筆衍生性交易。公開市場賣出合計 $27.0 萬。交易後 1 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Aurora Daljit SinghCIK 0001793971 | 高階主管（見申報備註） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/8/20 | Common Stock | M行使選擇權取得 | +67,741 | $0.72 | +$48,773.52 | 116,491 | 直接 | |
| 2026/8/20 | Common Stock | S賣出處分 | −67,741 | $1.51F1 | −$102,586.97 | 48,750 | 直接 | |
| 2026/8/20 | Common Stock | M行使選擇權取得 | +21,685 | $0.72 | +$15,613.2 | 21,685 | 間接 | |
| 2026/8/20 | Common Stock | M行使選擇權取得 | +45,026 | $0.72 | +$32,418.72 | 66,711 | 間接 | |
| 2026/8/20 | Common Stock | S賣出處分 | −66,711 | $1.51F2 | −$101,000.45 | 0 | 間接 | |
| 2026/8/21 | Common Stock | M行使選擇權取得 | +20,553 | $0.72 | +$14,798.16 | 69,303 | 直接 | |
| 2026/8/21 | Common Stock | S賣出處分 | −20,553 | $1.59F7 | −$32,779.98 | 48,750 | 直接 | |
| 2026/8/21 | Common Stock | M行使選擇權取得 | +21,055 | $0.72 | +$15,159.6 | 21,055 | 間接 | |
| 2026/8/21 | Common Stock | S賣出處分 | −21,055 | $1.60F8 | −$33,599.57 | 0 | 間接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/8/20 | Common Stock | M行使選擇權處分 | −67,741 | $0.00 | $0 | 109,527 | 直接 | |
| 2026/8/20 | Common Stock | M行使選擇權處分 | −45,026 | $0.00 | $0 | 0 | 間接 | |
| 2026/8/20 | Common Stock | M行使選擇權處分 | −21,685 | $0.00 | $0 | 115,853 | 間接 | |
| 2026/8/20 | Common Stock | A公司授予取得 | +200,000 | $0.00 | $0 | 200,000 | 直接 | |
| 2026/8/21 | Common Stock | M行使選擇權處分 | −20,553 | $0.00 | $0 | 88,974 | 直接 | |
| 2026/8/21 | Common Stock | M行使選擇權處分 | −21,055 | $0.00 | $0 | 94,798 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
This transaction was executed in multiple trades at prices ranging from $1.485 to $1.625, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F2
This transaction was executed in multiple trades at prices ranging from $1.48 to $1.6252, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F7
This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6379, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F8
This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6393, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
備註
Title: Chief Operating and Development Officer